SCHEDULE: FMR LLC & Johnson Report 9.5% Stake in CAMP4 Therapeutics

FMR LLC and Abigail P. Johnson have reported a 9.5% beneficial ownership stake in CAMP4 Therapeutics Corporation as of December 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson, through various entities, beneficially own 4,918,243 shares of CAMP4 THERAPEUTICS CORPORATION's common stock.
• This ownership represents 9.5% of the total outstanding common stock of CAMP4 THERAPEUTICS CORPORATION.
• FMR LLC holds sole voting power over 4,916,914 shares and sole dispositive power over 4,918,243 shares.
• Abigail P. Johnson holds sole dispositive power over 4,918,243 shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported ownership position.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine disclosure of a significant institutional stake, which can be interpreted as a neutral to slightly positive signal for CAMP4 Therapeutics, indicating continued confidence from a major investor.

Positives

• A significant beneficial ownership stake of 9.5% by FMR LLC and Abigail P. Johnson, a major institutional investor, which can be interpreted as a signal of confidence in CAMP4 Therapeutics Corporation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding CAMP4 Therapeutics Corporation's future performance or operations.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of CAMP4 THERAPEUTICS CORPORATION.

Industry Context

StockSavvy.ai notes that significant institutional ownership by entities like FMR LLC often signals confidence in a company's long-term prospects, particularly in the biotech sector where CAMP4 Therapeutics operates. Such a stake can provide a degree of stability and investor validation.

Stakeholder Impact

• Shareholders may view the significant institutional ownership by FMR LLC as a positive indicator of long-term confidence in CAMP4 Therapeutics Corporation.

Key Dates

Recommendation

The filing details a substantial, passive ownership stake by FMR LLC and Abigail P. Johnson, a prominent institutional investor. While this indicates a degree of confidence from a sophisticated investor, the Schedule 13G itself does not provide operational or financial performance data to warrant a 'buy' or 'sell' recommendation. Therefore, a 'hold' is appropriate for existing investors, suggesting continued monitoring of the company's fundamentals.

Keywords

CAMP4 THERAPEUTICS CORPORATION, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor